Cutler Group LP Kezar Life Sciences, Inc. Transaction History

Cutler Group LP

  • $307 Million
  • Q1 2024

A detailed history of Cutler Group LP transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Cutler Group LP holds 2,400 shares of KZR stock, worth $14,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,400
Previous 2,400 -0.0%
Holding current value
$14,136
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 18, 2024
SELL
$0.72 - $1.15 $3,816 - $6,094
-5,300 Reduced 68.83%
2,400 $2,000
Q3 2023

Nov 07, 2023
BUY
$1.08 - $2.54 $4,320 - $10,160
4,000 Added 108.11%
7,700 $9,000
Q2 2023

Jul 18, 2023
BUY
$2.31 - $3.06 $2,310 - $3,060
1,000 Added 37.04%
3,700 $9,000
Q4 2022

Feb 07, 2023
SELL
$6.39 - $8.8 $13,284 - $18,295
-2,079 Reduced 43.5%
2,700 $19,000
Q3 2022

Oct 25, 2022
SELL
$7.99 - $10.75 $87,011 - $117,067
-10,890 Reduced 69.5%
4,779 $41,000
Q2 2022

Aug 04, 2022
BUY
$4.58 - $17.13 $71,764 - $268,409
15,669 New
15,669 $129,000
Q1 2021

Apr 26, 2021
SELL
$5.24 - $6.99 $524 - $699
-100 Closed
0 $0
Q4 2020

Jan 21, 2021
SELL
$4.77 - $6.58 $476 - $658
-100 Reduced 50.0%
100 $0
Q3 2020

Oct 27, 2020
BUY
$4.36 - $5.5 $436 - $550
100 Added 100.0%
200 $0
Q2 2020

Jul 22, 2020
BUY
$3.6 - $7.75 $360 - $775
100 New
100 $0

Others Institutions Holding KZR

# of Institutions
4
Shares Held
1.54M
Call Options Held
0
Put Options Held
0
View Full List

About Kezar Life Sciences, Inc.

KZR Quotes by TradingView
  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $403M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email